A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
Status:
Completed
Trial end date:
2016-11-04
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy of three dose regimens of gefapixant
([MK-7264] 7.5 mg, 20 mg, and 50 mg) relative to placebo in reducing awake objective cough
frequency. The primary hypothesis for this trial is that at least one dose regimen of
gefapixant is superior to placebo with respect to the mean change from baseline in awake
cough frequency (on the log scale).